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DOI 10.1016/j.ccr.2010.08.013SUMMARYLung cancer is the leading cause of cancer-related deaths in the world, and non-small-cell lung cancer
(NSCLC) accounts for 80% of cases. MicroRNA-21 (miR-21) expression is increased and predicts poor
survival in NSCLC. Although miR-21 function has been studied in vitro with cancer cell lines, the role of
miR-21 in tumor development in vivo is unknown. We utilize transgenic mice with loss-of-function and
gain-of-function miR-21 alleles combined with a model of NSCLC to determine the role of miR-21 in lung
cancer. We show that overexpression of miR-21 enhances tumorigenesis and that genetic deletion of
miR-21 partially protects against tumor formation.MiR-21 drives tumorigenesis through inhibition of negative
regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.INTRODUCTION
MicroRNAs are evolutionarily conserved, endogenous, non-
protein-coding, 20–23 nucleotide single-stranded RNAs that
negatively regulate gene expression in a sequence-specific
manner (Cho, 2007; Esquela-Kerscher and Slack, 2006; Voo-
rhoeve and Agami, 2007). The human genome is predicted to
encode as many as 1000 miRNAs, or 3% of the total number
of human genes (Bartel, 2004; Esquela-Kerscher and Slack,
2006). The 50 portion of miRNA sequence containing bases
two to eight, termed the ‘‘seed’’ region, is important in target
mRNA recognition. miRNAs negatively regulate target gene
expression through complementarity between the miRNA seed
sequence and the target mRNA 30 untranslated region (UTR).
miRNAs that bind with perfect complementarity to the protein
encoding messenger RNA (mRNA) target the mRNA for destruc-
tion, whereas miRNAs with imperfect complementarity to theSignificance
MicroRNAs are small noncoding RNAs that are commonly dysre
the pathogenesis and survival of many cancers. MiR-21 is ove
non-small-cell lung cancer (NSCLC). However, it is not clear w
pathogenesis or is instead simply a marker for advanced disea
oncogenic K-ras activation and modulates NSCLC tumorigene
negative regulators of the Ras/MEK/ERK pathway, and Apaf1,
deletion also sensitizes cells to DNA-damaging chemotherapy
value.
282 Cancer Cell 18, 282–293, September 14, 2010 ª2010 Elsevier In30 UTR of the mRNA target repress mRNA translation. Expres-
sion of approximately 30% of human proteins appears to be
regulated by miRNAs (Lewis et al., 2005). Through interactions
with 30 UTRs, miRNAs can modulate the expression of many
genes simultaneously, often regulating individual signaling
pathways at multiple levels (Baek et al., 2008; Selbach et al.,
2008).
An integral role of miRNAs in cancer pathogenesis has begun
to emerge. miRNA expression profiling reveals characteristic
signatures for many tumor types, including non-small-cell lung
cancer (NSCLC) (Volinia et al., 2006), and are predictive of
tumor classification, prognosis, and response to therapy (Calin
and Croce, 2006). miRNA expression patterns are remarkably
reliable markers of cancers; in some cases, they have even
proven more reliable than conventional histology (Subramanian
et al., 2008). MicroRNAs are capable of functioning as classical
tumor suppressors or oncogenes, thus actively participatinggulated in humanmalignancies and play a substantial role in
rexpressed in the majority of human malignancies, including
hether miR-21 determines important aspects of lung cancer
se. We show in vivo that miR-21 expression increases with
sis by targeting Spry1, Spry2, Btg2, and Pdcd4, which act as
Faslg, Pdcd4, and RhoB, which promote apoptosis.MiR-21
, suggesting that miR-21 inhibition could be of therapeutic
c.
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Recently, gain- and loss-of-function studies in mice demon-
strate critical roles for miR-26a and miR-9 in hepatocellular
carcinoma and breast cancer metastasis, respectively (Kota
et al., 2009; Ma et al., 2010). These data suggest that the
pattern of miRNA expression contributes to fundamental
aspects of tumor biology.
A large-scale survey to determine the miRNA signature of
540 tumor samples—including lung, breast, stomach, prostate,
colon, and pancreatic tumors and their respective normal adja-
cent tissue—revealed miR-21 was the only miRNA upregulated
in all these tumors (Volinia et al., 2006). Further miRNA profiling
in tumor samples and cancer cell lines showed increased
miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre
et al., 2005), head and neck carcinomas (Tran et al., 2007),
ovarian cancer (Iorio et al., 2007), B cell lymphoma (Lawrie
et al., 2007), hepatocellular (Meng et al., 2007), and cervical
carcinoma (Lui et al., 2007). These studies clearly illustrate
miR-21 dysregulation in tumors; however, the studies do not
prove a causal role for miR-21 in cancer pathogenesis.
Functional studies in cancer cell lines suggest that miR-21 has
oncogenic activity. Knockdown of miR-21 in cultured glioblas-
toma cells activates caspases leading to apoptotic cell death,
suggesting miR-21 is an antiapoptotic factor (Chan et al.,
2005). In breast cancer MCF-7 cells, miR-21 knockdown results
in suppression of cell growth in vitro and tumor growth in xeno-
grafts (Si et al., 2007). Knockdown of miR-21 in the metastatic
breast cancer MD-MBA-231 cells reduced invasion and metas-
tasis (Zhu et al., 2008). Targeted deletion of miR-21 in RKO and
DLD1 colon cancer cells revealed that miR-21 contributes to
tumorigenesis through compromising cell cycle progression
and DNA damage-induced checkpoint function through the
CDC25A target gene (Wang et al., 2009). These studies indicate
knockdown of miR-21 expression in cancer cell lines results in
phenotypes important for tumor biology. However, the potential
role of miR-21 in tumorigenesis in vivo has not yet been
explored.
Lung cancer is the most common form of cancer in the world,
accounting for approximately 12.3% of all cancers with an esti-
mated 1.2 million new cases each year (Parkin et al., 2001). Lung
cancer is also the leading cause of cancer-related deaths in the
world, with NSCLC accounting for 80%of all cases (Ramalingam
et al., 1998). Despite novel therapies and advances in early
detection, NSCLC is often diagnosed at an advanced stage
and has a poor prognosis, with a median survival of 8 to
11 months and a 5 year survival rate in patients with NSCLC of
only 13% using conventional cytotoxic chemotherapy (Soon
et al., 2009). Recently, miR-21 expression levels have proven
useful prognostic markers in NSCLC (Markou et al., 2008; Yanai-
hara et al., 2006). The level of miR-21 expression in sputum
distinguishes patients with NSCLC from cancer-free control
subjects with a greater sensitivity than conventional cytology
(Xie et al., 2010). Currently, more experiments are needed to
determine whether miR-21 participates in driving the malignant
phenotype or simply reflects the cellular stress.
In the current study, we used transgenic mice with both loss-
of-function and gain-of-function miR-21 alleles in combination
with the K-rasLA2 mouse model of NSCLC to elucidate the role
of miR-21 in NSCLC pathogenesis.CanRESULTS
miR-21 Overexpression Promotes Tumor Development
In Vivo
Increased expression of miR-21 in human cancer could reflect
malignant physiology or could determine important aspects of
cancer biology. To address this question, we generated trans-
genic mice that overexpress the miR-21 gene and mice with
deletion of the miR-21 gene and tested the consequences in
a mouse model of NSCLC. We designed a strategy to condition-
ally overexpress miR-21 using the Cre-lox system and the CAG-
Z-EGFP vector (see Figure S1A and Supplemental Experimental
Procedures available online) (Fukuda et al., 2005). Global miR-21
overexpression was achieved by breeding the CAG-Z-miR21-
EGFP mouse to transgenic mice expressing Cre recombinase
from the ubiquitous CAG promoter resulting in the CAG-
miR-21 mouse, which globally overexpressed miR-21 4- to
6-fold over normal levels of expression (Figures S1B–S1D).
CAG-miR-21 transgenic mice were viable, fertile, and born in
expected Mendelian ratios. miR-21 expression increases in
mouse models of cardiac hypertrophy and following myocardial
infarction; however, adult male CAG-miR-21 mice showed no
signs of heart failure compared to littermate controls (Fig-
ure S1E) (van Rooij et al., 2006; van Rooij et al., 2008).
To explore the role of miR-21 in the pathogenesis of NSCLC,
we utilized the K-rasLA2 murine lung cancer model, which
harbors a targeted, latent K-ras G12D allele that is activated by
two distinct recombination events (Johnson et al., 2001). The first
occurs in ES cells, and the second occurs in vivo, resulting in the
random activation of the mutant K-ras G12D allele in somatic
cells. K-rasLA2 mice develop multifocal lung tumors with 100%
penetrance, and less frequently develop thymic lymphomas
and skin papillomas (Johnson et al., 2001). CAG-miR-21;
K-rasLA2 compound mutant mice were generated by breeding
to compare the number, rate of formation, and histology of
tumors relative to littermate control K-rasLA2 mice. Remarkably,
overexpression ofmiR-21 enhanced the number of tumors in this
model of lung cancer (Figures 1A–1C). Compared with K-rasLA2
littermates, CAG-miR-21;K-rasLA2 mice displayed significantly
more lung tumors visible grossly at 18 weeks (Figure 1D) and
microscopically on H&E cross-section over all time points
(Figure 1F). Total tumor area as a proportion of total lung
area was significantly increased with miR-21 overexpression
(Figure 1E).
Tumors in CAG-miR-21;K-rasLA2 mice exhibited increased
proliferation compared with K-rasLA2 control tumors (Fig-
ure 1G). Despite the increased tumor burden, the survival of
CAG-miR-21;K-rasLA2 mutant mice did not differ from K-rasLA2
control mice (Figure 1H). This may be explained by a decreased
incidence of thymic tumors in CAG-miR-21;K-rasLA2 mutant
mice compared to K-rasLA2 controls (Figure 1I), thus contributing
to the enhanced survival. Unlike K-rasLA1;p53/ compound
mutant mice (Johnson et al., 2001), we did not observe an
increased tumor spectrum or increased metastasis in the CAG-
miR-21;K-rasLA2mutant mice. miR-21 overexpression increased
the incidence of all tumor grades without increasing the rate of
conversion to adenocarcinoma, suggesting that miR-21 partici-
pates in tumor promotion rather than progression and metas-
tasis in this model (Figures 1J and 1K). miR-21 overexpressioncer Cell 18, 282–293, September 14, 2010 ª2010 Elsevier Inc. 283
Figure 1. miR-21 Overexpression Enhances Tumor Formation in the K-rasLA2 Mouse Model of NSCLC
(A) Gross (A) and cross-sectional (B and C) H&E histology of lungs isolated from CAG-miR-21;K-rasLA2mice and K-rasLA2 littermate controls at 18 weeks of age.
The image in (C) showsmagnification of boxed lesions in (B). Arrows in top and bottompanels indicate a hyperplastic lesion and adenoma, respectively. The scale
bars represent 5 mm (B) and 200 mm (C).
(D) Nodules grossly visible were counted on the lung surface of CAG-miR-21;K-rasLA2 (n = 5) and K-rasLA2 (n = 4) mice sacrificed at 18 weeks of age. Results
represent mean ± SEM; p = 0.013 with two-tailed, unpaired Student’s t test.
(E) Tumor burden measured as the ratio of total tumor area to total lung area of the lungs counted in (D). Results are mean ± SEM; p = 0.045 using two-tailed,
unpaired Student’s t test.
(F) Quantification of tumor lesions on lung H&E cross-section fromCAG-miR-21;K-rasLA2 (n = 49) andK-rasLA2 (n = 40) mice over time. Slopes were determined by
linear regression; p = 0.0027.
(G) Quantification of proliferating cells detected by Ki67 antibody immunostaining of lung tumors. Results are mean ± SEM (n = 12); p = 0.01 by two-tailed,
unpaired Student’s t test.
(H) Survival curve of CAG-miR-21;K-rasLA2 (n = 27) and K-rasLA2 (n = 32) mice (p = 0.367) with median survival of 270 and 203 days, respectively; for WT mice,
n = 10; for CAG-miR-21 mice, n = 20.
(I) Tumor spectra in CAG-miR-21;K-rasLA2 (n = 27) and K-rasLA2 mice (n = 32).
(J) Lung H&E cross-sections fromCAG-miR-21;K-rasLA2 (n = 27) and K-rasLA2 (n = 32) mice in the survival cohort were analyzed, and all lesions were classified for
tumor grade. For hyperplasia, p < 0.0001. For atypical adenomatous hyperplasia, p = 0.017. For adenoma, p% 0.0001. For adenomawith atypia, p = 0.0042. For
adenocarcinoma, p = 0.033. All data are represented as the mean ± SEM of the number of lesions per lung.
(K) Rate of conversion of adenoma to adenocarcinoma. Data are presented as mean ± SEM (p = 0.83). See also Figure S1.
Cancer Cell
Role of MicroRNA-21 in Lung Tumor Pathogenesis
284 Cancer Cell 18, 282–293, September 14, 2010 ª2010 Elsevier Inc.
Cancer Cell
Role of MicroRNA-21 in Lung Tumor Pathogenesisdid not increase the rate of recombination of the K-rasLA2 allele
(Figure S1F). We followed CAG-miR-21 mice (n = 39) without
K-rasLA2 for up to 555 days and performed full necropsy and
histological analysis on H&E sections of the following tissues:
lung, heart, brain, spleen, liver, kidney, stomach, colon, skeletal
muscle, and bone marrow. No tumors were observed in CAG-
miR-21 mice without K-rasLA2, indicating that miR-21 overex-
pression alone is not sufficient for tumorigenesis. These data
suggest that miR-21 overexpression in human tumors does not
simply reflect cancer pathology, but instead enhances aspects
of the pathology of NSCLC.
miR-21 Deletion Suppresses Ras-Driven
Transformation In Vitro
To address the necessity of miR-21 in the development of
NSCLC, we generated miR-21 knockout mice. Homozygous
miR-21 knock-out mice are viable, fertile, and born in expected
Mendelian ratios without any gross phenotypic differences
compared to wild-type or heterozygous littermates, and without
a cardiac phenotype (D.P., E.V.R., and E.N.O., unpublished
data). To dissect the role of miR-21 in Ras-driven transforma-
tion, we isolated mouse embryonic fibroblasts (MEFs) from wild-
type and miR-21/ mice. Northern blot analysis and real-time
PCR confirmed deletion of miR-21 (Figures S2A and S2B).
These MEFs were immortalized and transformed with ret-
roviruses expressing SV40 large T and small t antigens and
H-rasG12V. There was no difference in proliferation between the
miR-21/ and wild-type MEFs (Figure S2C). However, the
miR-21/ MEFs formed significantly less colonies in soft
agar than wild-type MEFs (Figure S2D) and developed smaller
tumors in xenografts in nude mice (Figure S2E). These observa-
tions suggest that miR-21 actively participates in Ras-driven
transformation.
miR-21 Deletion Suppresses Tumor Development
In Vivo
Given that high levels of miR-21 expression in patients with
NSCLC serve as an independent negative prognostic factor
and that miR-21-deficient MEFs form fewer colonies in soft
agar, we hypothesized that genetic deletion of miR-21 in the
K-rasLA2 model would alter tumorigenesis. To explore this
possibility, we crossed the miR-21/ allele into the K-rasLA2
NSCLC model. Significantly fewer tumors were present on the
surface of the lungs of 20-week-old miR-21/;K-rasLA2 com-
pound mutant mice compared to K-rasLA2 control mice (Figures
2A–2C). Total tumor area as a proportion of total lung area
was significantly decreased with miR-21 deletion (Figure 2D).
miR-21 deletion did not alter proliferation in tumors measured
by Ki67 staining (Figure 2E).miR21/;K-rasLA2 mice all develop
lung tumors, but show an increased incidence of thymic
lymphoma (Figure 2F). miR-21/;K-rasLA2 mutant mice dis-
played a reduced incidence of hyperplasic lesions and
adenomas compared to K-rasLA2 controls (Figure 2G). Although
not statistically significant, there was a trend toward decreased
conversion of hyperplasia to adenoma in the miR-21/;
K-rasLA2 mice (Figure 2H). No adenocarcinomas were noted
in any of the 14 miR-21//K-rasLA2 animals evaluated. These
results illustrate that miR-21 deletion suppresses tumor devel-
opment in vivo.CanmiR-21 Targets Multiple Tumor Suppressor Genes
To identify miR-21 effectors responsible for phenotypes
observed, we utilized two algorithms that predict the mRNA
targets of miRNAs, TargetScan (Grimson et al., 2007), and Pic-
Tar (Krek et al., 2005). Approximately 180 mRNAs are predicted
as miR-21 target genes on the basis of the presence of miR-21
sites in their 30 UTRs. Many of the miR-21-predicted targets
have been reported to function as tumor suppressors and have
been validated in vitro in previous studies (Selcuklu et al., 2009).
We cloned the 30 UTRs of 24 putative mouse miR-21 target
genes into a luciferase reporter construct. Reporter assays in
COS cells revealed miR-21-dependent repression of 13 of
the 24 30 UTRs, and mutation of the miR-21 site in the 30 UTR
abrogated the repression in 11 of the putative target gene 30
UTRs (Figure 3A). Four of the validated miR-21 target genes
are known negative regulators of the Ras/MEK/ERK path-
way: sprouty 1 (Spry1), sprouty 2 (Spry2), B cell translocation
gene 2 (Btg2), and programmed cell death 4 (Pdcd4). Several
proapoptotic genes were directly targeted by miR-21, apoptotic
peptidase activating factor 1 (Apaf1), Fas ligand (Faslg), Pdcd4,
and ras homolog gene family member B (RhoB). We show
miR-21-dependent repression of the mouse Apaf1 30 UTR
reporter; however, the miR-21 site in the human APAF1 30
UTR is conserved in primates but not conserved in the
mouse. Eleven of the putative miR-21 target gene 30 UTRs,
including phosphatase and tensin homolog (Pten), were not
repressed by miR-21 (Figure 3B). Caspase 3 and K-ras do
not contain miR-21 sites in their 30 UTR, and the 30 UTR
luciferase reporter activity is not suppressed by miR-21 (Fig-
ure 3B). These results suggest that in vitro miR-21 can repress
multiple tumor suppressor genes that may participate in
tumorigenesis.
Oncogenic Ras Activation Increases miR-21 Expression
In Vivo
Previously, an autoregulatory loop connecting miR-21 and
Ras activation through AP-1 was illustrated in a rat thyroid
cell system (Talotta et al., 2009). miR-21 expression was
induced by AP-1 in response to Ras activation, and miR-21
mediated Ras-dependent downregulation of Pdcd4 (Talotta
et al., 2009), a known negative regulator of AP-1 transactivation
(Goke et al., 2004; Jansen et al., 2005; Yang et al., 2003; Yang
et al., 2001). In addition, epidermal growth factor receptor
(EGFR) and HER2/neu signaling positively regulates miR-21
expression in human lung and breast carcinoma cell lines,
respectively (Huang et al., 2009; Seike et al., 2009). We con-
firmed this autoregulatory loop in vivo by analyzing miR-21
expression in normal lung and tumors of K-rasLA2 and CAG-
miR-21;K-rasLA2 mutant mice. Normal lung tissue from K-rasLA2
mice (prior to K-ras activation) exhibits wild-type expression
levels of miR-21 (Figures 4A and 4B). K-ras activation in
the tumors of K-rasLA2 mice increased miR-21 expression by
4-fold, similar to the expression level in the CAG-miR-21 trans-
genic mouse lung. In CAG-miR-21;K-rasLA2 tumors, miR-21
expression was more than additive compared to either CAG-
miR-21 or K-rasLA2 mice alone. We speculate that, by driving
miR-21 expression in the transgenic mouse, we provided
a ‘‘second hit’’ prior to K-ras activation, thus accelerating tumor
initiation.cer Cell 18, 282–293, September 14, 2010 ª2010 Elsevier Inc. 285
Figure 2. miR-21 Deletion Suppresses Tumorigenesis in K-rasLA2 Model of NSCLC
(A and B) Gross (A) and cross-sectional (B) H&E histology of lungs isolated frommiR-21/;K-rasLA2 and K-rasLA2mice at 20 weeks of age. The scale bar repre-
sents 5 mm.
(C) Quantification of nodules grossly visible on the lung surface of miR-21/;K-rasLA2 (n = 5) and K-rasLA2 (n = 3) mice at 20 weeks of age. Results are mean ±
SEM; p = 0.008 using two-tailed, unpaired Student’s t test.
(D) Tumor burden measured as the ratio of total tumor area to total lung area of the lungs counted in (C). Results are mean ± SEM; p = 0.015 using two-tailed,
unpaired Student’s t test.
(E) Quantification of proliferating cells detected by Ki67 antibody immunostaining of lung tumors. Results are mean ± SEM (n = 6); p = 0.4 by two-tailed, unpaired
Student’s t test.
(F) Tumor spectra in K-rasLA2 and miR-21/;K-rasLA2 mice.
(G) LungH&E cross-sections frommiR-21/;K-rasLA2 (n = 14)mice.K-rasLA2 (n = 6) micewere analyzed and all lesions were classified for tumor grade. For hyper-
plasia, p = 0.023. For adenoma, p = 0.057. All data are represented as the mean ± SEM of the number of lesions per lung.
(H) Rate of conversion of hyperplasia to adenoma. Data are presented as mean ± SEM; p = 0.089. See also Figure S2.
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of Ras Signaling
Multiple negative regulators of the Ras/MEK/ERK pathway were
shown to be direct miR-21 target genes by luciferase reporter
assays (Figure 3B). Although there have been reports of
miR-21 target gene regulation in cancer cell lines, the constella-
tion of genes regulated by miR-21 in NSCLC in vivo remains
elusive. We hypothesize that increased miR-21 expression
potentiates Ras signaling through inhibition of antagonists of
the Ras pathway, such as Spry1, Spry2, Btg2, and Pdcd4 (Casci
et al., 1999; Hanafusa et al., 2002; Lo et al., 2006).
We isolated individual tumors from mice, made whole tumor
lysates, and performed western blots for putative miR-21 targets
to address the effect of miR-21 expression on the protein
levels of the miR-21 target genes in vivo within lung tumors.
miR-21 overexpression in CAG-miR-21;K-rasLA2 mutant tumors
decreases Spry1, Spry2, and Btg2 protein expression compared286 Cancer Cell 18, 282–293, September 14, 2010 ª2010 Elsevier Into K-rasLA2 tumors (Figure 4C). The decrease in Spry1, Spry2,
and Btg2 in CAG-miR-21;K-rasLA2 tumors correlates with
increased Ras pathway activity, shown by increased ERK phos-
phorylation (Figure 4C). miR-21/;K-rasLA2 mutant tumors did
not show alteration in the regulation of ERK by Spry1, Spry2,
and Btg2 (Figure 4D). Protein analysis of individually isolated
tumors showed that Pdcd4 levels were decreased in CAG-
miR-21;K-rasLA2 compound mutant mice compared to K-rasLA2
control tumors (Figure 4C). This regulation was absent in tumors
from the miR-21/;K-rasLA2 compound mutant mice (Fig-
ure 4D). RECK, Cdc25a, Map2k3, NfiB, Trp63, and Ski have
been shown to be miR-21 target genes in vitro, but only RECK
showed decreased protein levels in the CAG-miR-21;K-rasLA2
tumors (Figure S3A). Several components of the PI3K pathway,
including PTEN and PIK3R1, have been suggested as miR-21
target genes (Meng et al., 2007); however, miR-21 overexpres-
sion did not alter PTEN and PIK3R1 protein expression or Aktc.
Figure 3. miR-21 Targets mRNAs Encoding
Multiple Tumor Suppressors
(A) Luciferase activity in COS cells cotransfected
with miR-21 or control vector andmiR-21-respon-
sive target gene 30 UTRs or miR-21 site mutant 30
UTR luciferase reporters. Data are presented as
mean ± SEM and normalized to empty vector (no
miR-21) control (n = 4).
(B) Luciferase activity in COS cells cotransfected
with miR-21 or empty vector and indicated
miR-21 unresponsive 30 UTRs. Data are presented
as mean ± SEM and normalized to empty vector
(no miR-21) control (n = 4).
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overexpression decreases the protein expression of four
miR-21 target genes that are tumor suppressors and negative
regulators of the Ras/MEK/ERK pathway, resulting in a concom-
itant increased ERK activity.Cancer Cell 18, 282–293, SemiR-21 Suppresses Apoptosis
by Targeting Proapoptotic Genes
Next, we evaluated the effect of miR-21
expression on apoptosis. MiR-21 overex-
pression in CAG-miR-21;K-rasLA2 mice
reduced apoptosis in lung tumors, as
shown by TUNEL staining (Figures 5A
and 5B). Deletion of miR-21 had no effect
on the amount of apoptosis in the lung
lesions, as detected by TUNEL, suggest-
ing that lung tumors that develop in thebackground of the genetic deletion of miR-21 have escaped
miR-21 regulatory effects (Figure 5C). Several miR-21 target
genes are tumor suppressors involved in apoptosis, including
Apaf11, Pdcd4, RhoB, and Faslg. Lysates from individually
isolated tumors from CAG-miR-21;K-rasLA2 mice showedFigure 4. miR-21 Induction by Oncogenic
K-Ras Represses Negative Regulators of
the Ras/MEK/ERK Pathway
(A) MiR-21 expression in lung tumors from CAG-
miR-21;K-rasLA2 and K-rasLA2 mice (after K-ras
activation) compared to normal lung from wild-
type (WT), K-rasLA2 (prior to K-ras activation), and
CAG-miR-21 mice by real-time PCR. Results
represent mean ± SEM.
(B) Northern blot analysis of miR-21 expression
in lung tumors from CAG-miR-21;K-rasLA2 and
K-rasLA2 mice (after K-ras activation) compared
to normal lung from WT, K-rasLA2 (prior to K-ras
activation), and CAG-miR-21 mice.
(C) Western blot analysis of lung lysates from
normal lung from WT and CAG-miR-21 mice and
six isolated lung tumors from CAG-miR-21;K-
rasLA2 and K-rasLA2 mice. Antibodies used are
shown on right.
(D) Western blot analysis of lung lysates from WT
and miR-21/ mice and six isolated tumors
from miR-21/;K-rasLA2 and K-rasLA2 mice. Anti-
bodies used are shown on right. See also
Figure S3.
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Figure 5. miR-21 Reduces Apoptosis
through Targeting Multiple Apoptotic
Modulators
(A) TUNEL staining of K-rasLA2 and CAG-miR-21;
K-rasLA2 tumors. Scale bars represent 20 mm.
(B) Quantification of TUNEL-positive nuclei
per lung tumor in K-rasLA2 (n = 16) and CAG-
miR-21;K-rasLA2 (n = 62) mice. Results are
mean ± SEM; p = 0.007 by unpaired, two-tailed
Student’s t test.
(C) Quantification of TUNEL staining inmiR-21/;
K-rasLA2 (n = 22) mice and K-rasLA2 controls.
Results are mean ± SEM; p = 0.28 with unpaired,
two-tailed Student’s t test.
(D) Western blot analysis of lung lysates from wild-
type (WT) and CAG-miR-21 mice and six isolated
lung tumors from CAG-miR-21;K-rasLA2 and
K-rasLA2 mice. Antibodies used are shown on
right.
(E) Western blot analysis of lung lysates from WT
and miR-21/ mice and six isolated lung tumors
from miR-21/;K-rasLA2 and K-rasLA2 mice. Anti-
bodies are shown on right.
(F) Quantification of protein expression from
Western blots shown in Figure 4C, Figure 5D,
and Figures S3A and S3B. Bar values indicate
the mean ± SEM of protein levels in six indepen-
dent tumors from CAG-miR-21;K-rasLA2 mice
after normalization to GAPDH and represented
as fraction of the protein levels in the K-rasLA2
controls. Dashed line indicates the protein level
in K-rasLA2 tumors.
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RhoB (Figures 4C and 5D). MiR-21/;K-rasLA2 mutant tumors
did not show alteration in the regulation of Apaf1 or Faslg
(Figure 5E). Apaf1, Pdcd4, Faslg, and RhoB were validated
as direct miR-21 target genes by luciferase reporter assays;
however, caspase 3 was not directly regulated by miR-21
(Figure 3B). Quantification of miR-21 target Western blots is
shown in Figure 5F. These data illustrate that miR-21 overex-
pression decreases the protein expression of four miR-21 target
genes that are involved in apoptosis thus promoting survival.
miR-21 Deletion Sensitizes Cells to DNA-Damaging
Chemotherapy
Recent studies illustrate that miRNAs modulate sensitivity of
cells to chemotherapy (Blower et al., 2008). We utilized the
miR-21/ andwild-typeMEFs immortalized with TAg and trans-
formed with RasV12 to test the role of miR-21 in doxorubicin-
induced apoptosis. MEFs were cultured with increasing concen-
trations of doxorubicin, whole cell lysates were isolated, and
apoptotic activity was measured by immunoblotting for cleaved
caspase 3. MEFs frommiR-21/ mice display increased sensi-
tivity to doxorubicin-induced apoptosis measured by protein
levels of cleaved caspase 3 (Figure 6A). miR-21/ MEFs were
transduced with a lentivirus expressing miR-21 to rescue the
miR-21 deficiency (Figure S4). Lentiviral overexpression of288 Cancer Cell 18, 282–293, September 14, 2010 ª2010 Elsevier InmiR-21 decreased cleaved caspase 3 levels compared to empty
lentiviral transduced miR-21/ MEFs. The increased sensitivity
to doxorubicin-induced apoptosis measured by cleaved cas-
pase 3 levels was confirmed by TUNEL (Figure 6C). Therefore,
miR-21 plays a significant role in inhibition of apoptosis thus
allowing tumor survival.
DISCUSSION
Our results show that miR-21 expression modulates tumor
number, incidence, and size in a mouse lung cancer model initi-
ated by oncogenic K-rasG12D, consistent with miR-21 func-
tioning as a tumor promoter. miR-21 was not sufficient in our
model for tumorigenesis; however, under the control of other
tissue-specific promoters, miR-21 could have cancer related
phenotypes. miR-21 modulates several components critical to
NSCLC pathogenesis through both relieving antagonism of
the Ras pathway and reducing apoptotic effectors (Figure 7).
Although we show regulation of protein levels of miR-21 target
genes with miR-21 overexpression, we do not observe robust
changes in protein levels on miR-21 target genes with miR-21
deletion, suggesting that miR-21 may act through additional
mechanisms. By targeting antagonists of Ras/MEK/ERK sig-
naling and proapoptotic genes, miR-21 enhances tumor prolifer-
ation and survival, two critical components of tumor promotion.c.
Figure 6. miR-21 Deletion Sensitizes Cells
to Doxorubicin-Induced Apoptosis
(A) Western blot analysis (left panel) for cleaved
caspase 3 in protein lysates from wild-type and
miR-21/ MEFs immortalized with T-Ag, trans-
formed with H-rasV12, and treated with increasing
concentrations of doxorubicin. Antibodies used
are shown on right. Quantification of cleaved cas-
pase 3 levels normalized to pro-caspase 3 and
represented relative to untreated wild-type MEFs
(right panel).
(B) Western blot analysis (left panel) for cleaved
caspase 3 in protein lysates from miR-21/
MEFs immortalized with T-Ag, transformed with
H-rasV12, and transduced with lentivirus express-
ing miR-21 (lenti-miR-21) or empty vector, and
treated with increasing concentrations of doxoru-
bicin. Antibodies used are shown on right. Quanti-
fication of cleaved caspase 3 levels normalized
to pro-caspase 3 and represented relative to
untreated wild-type MEFs (right panel).
(C) TUNEL assay of wild-type and miR-21/
MEFs treated with vehicle or 1 mM doxorubicin
for 12 hr. Data are presented as mean ± SEM
(n = 6). See also Figure S4.
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Role of MicroRNA-21 in Lung Tumor PathogenesisOur results define in vivo an autoregulatory loop between
oncogenic Ras and miR-21 mediated by Spry1, Spry2, Btg2,
and Pdcd4. PDCD4 is a proapoptotic tumor suppressor
gene and has been verified as a miR-21 target in human colo-
rectal and breast cancer cell lines (Afonja et al., 2004; Asangani
et al., 2008; Bitomsky et al., 2008; Frankel et al., 2008; Lu et al.,
2008; Zhang et al., 2006). Pdcd4 functions both as an inducer of
apoptosis and a suppressor of AP-1 activity (Hwang et al., 2007).Figure 7. Autoregulatory Loop between Ras and miR-21
Proposed model showing that miR-21 potentiates oncogenic Ras signaling
and attenuates apoptosis through repression of multiple tumor suppessors
and miR-21 target genes.
Cancer Cell 18, 282–293, SeLoss of PDCD4 expression in human
lung cancer correlates with higher grade
and disease stage (Chen et al., 2003).
MiR-21 targetsSPRY2 in cardiomyocytes
and SW480 colon cancer cells, enhanc-
ing cell migration (Sayed et al., 2008).
SPRY2, in turn, negatively regulates
Ras/MEK/ERK signaling and is a tumorsuppressor in NSCLC in both mice (Minowada and Miller,
2004;Minowada andMiller, 2009; Shaw et al., 2007) and humans
(Sutterluty et al., 2007). In laryngeal carcinoma, miR-21 targets
BTG2 (Liu et al., 2009), a p53 target gene, recently shown to
suppress oncogenic Ras activity by reducing the GTP-bound,
active state (Buganim et al., 2010). Although the reductions in
protein levels of individual miR-21 targets appear modest with
miR-21 overexpression, collectively this diminution of tumor
suppressor activity allows for more robust tumor formation
through relieving multiple nodes of inhibition of the Ras/MEK/
ERK pathway, thus facilitating tumor proliferation.
Oncogenic Ras activation has been shown to increase the
expression of Spry2, providing feedback inhibition of Ras activa-
tion (Shaw et al., 2007). We show that Ras activation increases
miR-21 expression and, in turn, decreases the expression of
Spry2. The genetic deletion ofmiR-21 removes themiR-21medi-
ated downregulation of Spry2, resulting in more Spry2-mediated
Ras/MEK/ERK inhibition and tumor suppressor activity. We
postulate that the tumors formed in the background of miR-21
deletion have developed escape mechanisms to circumvent
the Spry2 tumor suppressor activity. The necessity to circum-
vent the lack of miR-21 protumorigenic effects could explain
the latency of tumor formation in the miR-21/ mice.
Previous work in cancer cell lines has implicated miR-21 as
a suppressor of apoptosis. Knock-down of miR-21 in glioblas-
toma cell lines triggers the activation of caspases and increasesptember 14, 2010 ª2010 Elsevier Inc. 289
Cancer Cell
Role of MicroRNA-21 in Lung Tumor Pathogenesisapoptosis (Chan et al., 2005). Zhang et al. (2008) showed in
a human gastric cancer cell line that forced overexpression of
miR-21 enhanced tumor proliferation and invasion and knock-
down of miR-21 resulted in a marked reduction in proliferation
and increase in apoptosis. The present work illustrates in vivo
that increased expression of miR-21 significantly reduces apo-
ptosis in mouse lung tumors. MiR-21 overexpression resulted
in reduced protein levels of Apaf1, a key component of the
intrinsic, mitochondrial apoptotic pathway, as well as decreased
expression of Faslg, a key initiator of the extrinsic, death receptor
apoptotic pathway. Faslg mRNA is expressed in human lung
tumors; however, the Faslg protein is only detected in a small
fraction of lung tumors (Badillo-Almaraz et al., 2003). miR-21-
mediated translational inhibition could partially explain this find-
ing. Overexpression of miR-21 correlated with a decrease RhoB
protein levels. RhoB promotes growth inhibition and induces
apoptosis in cancer cells (Kim et al., 2009), andRhoB expression
is downregulated in human NSCLC, suggesting a role as a tumor
suppressor gene (Sato et al., 2007). Relieving miR-21 inhibition
of proapoptotic genes could provide a means to augment the
effect of current chemotherapy.
Methods have been developed to manipulate miRNA function
pharmacologically, facilitating the development of new cancer
therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al.,
2005). Increased sensitivity to DNA-damaging agents in the
miR-21/-transformed MEFs suggests that inhibition of miR-21
could provide a therapeutic strategy in NSCLC. In addition,
inhibiting miR-21 potentially restores the activity of multiple
tumor suppressors acting at various critical nodes of tumor
development. Here we report an in vivo, functional role of
miR-21 in NSCLC.
EXPERIMENTAL PROCEDURES
Mouse Strains
K-rasLA2 mice in the B6.129S background were provided by T. Jacks (Massa-
chusetts Institute of Technology) through the National Cancer Institute.
Construction of CAG-Z-miR-21-EGFP transgenic mice is detailed in Supple-
mental Experimental Procedures. All mice used in these studies were of mixed
genetic backgrounds, and all comparisons were performed on littermate
controls. The CAG-miR-21 transgenic mice (B6C3F1 background) were bred
to K-rasLA2 mice to generate miR-21 overexpressing CAG-miR-21;K-rasLA2
compound mutant mice and control K-rasLA2 mice. The miR-21/ mice
(B6.129SvEv) were bred to K-rasLA2 mice to generate miR-21-deficient miR-
21/;K-rasLA2 compound mutant mice and control K-rasLA2 mice. Mice
were sacrificed at stated time points or when showing obvious tumor burden
or distress, and a full necropsy was performed. All experimental procedures
involving animals in this study were reviewed and approved by the Institutional
Animal Care and Use Committee at the University of Texas Southwestern
Medical Center. For survival analysis, CAG-miR-21;K-rasLA2 and K-rasLA2
mice were observed daily from birth and were sacrificed at the first sign of
shortness of breath, reduced locomotion, or reduced body weight (>20% of
total body weight).
RNA Purification, RT-PCR, and Real-Time PCR
Total RNA was isolated from normal lung or lung tumors with Trizol reagent
(Invitrogen) according to the manufacturer’s protocol. miRNA levels were
determined by Northern blot analysis and real-time PCR. RT-PCR was per-
formed using the TaqMan microRNA reverse-transcriptase kit (Applied
Biosystems). Real-time PCR was performed using TaqMan probes on an
ABI-PE Prism 7000 sequence detection system according to the manufac-
turer’s protocol. The relative quantities of miRNA were determined using the
CTmethod and were normalized to RNU6B. The recombination of the K-rasLA2290 Cancer Cell 18, 282–293, September 14, 2010 ª2010 Elsevier Inallele was determined by RT-PCR. Total RNA was isolated from microdis-
sected normal lung and lung tumors. Reverse transcription was performed
using random hexamer primers and SuperScript III First-Strand Synthesis
(Invitrogen). PCR primers used and conditions were previously described
(Johnson et al., 2001).
Northern Blot Analysis
Ten micrograms of total RNA from different tissues or tumors was resolved on
a 20% polyacrylamide (7.6 M urea) gel in 13 TBE. RNA was then transferred
onto a Zetaprobe GT membrane (Bio-Rad) in 0.53 TBE buffer at 80 V for
1 hr. Hybridization was performed at 39C. 32P-labeled Star-Fire oligonucleo-
tide probes (IDT) against thematuremiR-21 andU6were used in hybridization.
U6 was used as a loading control.
Histology, Immunohistochemistry, and TUNEL
For determining tumor incidence and grade, whole lungs were manually
inflated with 10% neutral-buffered formalin, placed in fixative for 3 days,
embedded in paraffin, and sectioned at the level of the tracheal bifurcation
at 5 mm intervals. H&E stains were performed using standard procedures.
Lung and tumor areas were determined using ImageJ software. Tumor burden
was expressed as the sum of the tumor area divided by the total lung area.
Proliferation was assessed by immunohistochemistry using antibodies against
Ki67 (Abcam). Paraffin-embedded sections were deparaffinized, heated in
a microwave in 0.01 M sodium citrate buffer for antigen retrieval, treated
with 3% H2O2 for 10 min, and rinsed in H2O and PBS. Sections were blocked
in 5% goat serum in PBS followed incubation with anti-Ki67 antibody (Abcam).
Signals were detected with Vectastain ABC kit (Vector Laboratories) and
3,30-diaminobenzidine (DAB) substrate (Vector Laboratories). Sections were
counterstainedwith hematoxylin andmounted. Ki67 positive cells were scored
per high-power field from three separate animals (four tumors per animal), and
each genotype and represented as themean percentage of the total number of
cells ± SEM. Apoptosis was evaluated by staining paraffin sections with In situ
cell death detection kit, TMR red terminal deoxynucleotidyl-transferase-
mediated dUTP nick-end labeling (TUNEL) system (Roche) according to the
manufacturer’s protocol. Slides were mounted with Vectashield mounting
medium with DAPI (Vector Laboratories). The number of apoptotic cells per
lung tumor were recorded and presented as the mean ± SEM.
Tumor Grading
All tumors from the survival cohort were analyzed on H&E sections and
categorized as hyperplasia, atypical adenomatous hyperplasia, adenoma,
adenoma with typia, and adenocarcinoma, according to the Mouse Models
of Human Cancer Consortium recommendations (Nikitin et al., 2004).
Western Blot Analysis
Individual tumors weremicrodissected from the lungs and snap frozen in liquid
nitrogen. Individual tumor and lung lysates were prepared in RIPA with
protease inhibitors (Roche complete mini) and phosphatase inhibitor cocktail
(Sigma) using a manual pestle homogenizer and clarified by centrifugation at
12,000 g for 10 min at 4C. Protein concentration was determined by BCA
assay (Themo Scientific), and equivalent amounts were resolved by SDS-
PAGE and immunoblotted by a standard protocol. Antibodies were purchased
from Abcam (Spry1, Spry2, Btg2, NfiB, Ski, and Trp63), Cell Signaling (phos-
phor-ERK, total ERK, total Caspase 3, Apaf1, RhoB, PTEN, PIK3R1, phos-
phor-Akt(Ser473), total Akt, RECK, Cdc25a, and Map2k3), Chemicon (GAPDH
and Faslg), and Rockland (Pdcd4). Quantification of Western blots was per-
formed by densitometry using NIH ImageJ software. Each sample was normal-
ized to GAPDH and represented as a fraction of K-rasLA2 control tumors.
Reporter Assays
The 466 base-pair genomic fragment encompassingmiR-21 was amplified by
PCR and ligated into pCMV6. Full-length 30 UTRs of putative miR-21 target
genes were cloned from mouse 129SvEv genomic DNA and subcloned into
the pMiR-report vector (Ambion). Mutations in the putative miR-21 site in the
30 UTRs were generated by QuickChange mutagenesis (Stratagene) to alter
the second and third nucleotides of the targeting sequence. Cell culture, trans-
fection, and luciferase reporter assays were performed as previously
described (van Rooij et al., 2008).c.
Cancer Cell
Role of MicroRNA-21 in Lung Tumor PathogenesisDoxorubicin-Induced Apoptosis
Wild-type and miR-21/ MEFs immortalized with T-Ag and transformed with
H-rasV12 were seeded in a 6-well plate at 1 3 105 cells per well. Cells were
treated with vehicle control and increasing doxorubicin concentrations from
100 nM to 10 mM for 12 hr. Cells were lysed in RIPA, and protein concentrations
were determined by BCA (Thermo Scientific). Western blotting of 50 mg of
lysates was performed with antibodies directed against pro- and cleaved
Caspase 3 (Cell Signaling) and GAPDH (Chemicon). Quantification of Western
blots was performed by densitometry using NIH ImageJ software. Cleaved
caspase 3 levels were expressed as a ratio of pro-caspase 3 and were normal-
ized to either WT untreated or empty vector untreated samples. For TUNEL
assays, MEFs were seeded in a 6-well plate at 13 105 cells per well on cover-
slips. Cells were treated with vehicle control or 1 mM doxorubicin for 12 hr.
TUNEL was performed using an in situ cell death detection kit, TMR red
terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling
(TUNEL) system (Roche) according to manufacturer’s protocol.
Statistical Analysis
Results are expressed as the mean ± SEM. We utilized a two-tailed, unpaired
Student’s t test for all pair-wise comparisons (GraphPad Prism version 5).
p values less than 0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2010.08.013.
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